Filing and business context
Filing identity: The supplied filing is Calyxt, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 11, 2019—not a Cibus, Inc. filing. The “2018 Q4” label refers to the annual filing; quarterly figures are included below where relevant. Calyxt develops gene-edited crops and food ingredients, led by its high-oleic soybean product. It reported no product sales in 2018; initial sales of soybean oil and meal occurred in the first quarter of 2019.
Financial performance and position
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $0.236 million | $0.508 million | Down 53.5% |
| Research and development | $9.846 million | $11.556 million | Down 14.8% |
| Selling, general and administrative | $18.505 million | $14.741 million | Up 25.5% |
| Net loss | $27.897 million | $25.980 million | Loss increased 7.8% |
| Basic and diluted loss per share | $0.91 | $1.12 | Smaller loss per share |
| Cash used in operating activities | $20.252 million | $12.785 million | Use increased |
Revenue was primarily from technology licensing, not product sales. Gross margin is not meaningful as a commercial-product measure for 2018: revenue was minimal and reported cost of revenue was zero. Management attributed the R&D expense decline mainly to lower stock-based compensation, partly offset by grain purchases and employee costs. Higher SG&A reflected commercial-readiness hiring, public-company costs and executive turnover.
At year-end, cash and cash equivalents were $93.794 million, with $1.494 million of restricted cash, for total cash, cash equivalents and restricted cash of $95.288 million. Total assets were $118.791 million; total liabilities were $25.394 million. Financing lease obligations had a carrying value of about $18.5 million, including $0.258 million current, and $31.127 million of undiscounted future financing-lease payments. No conventional borrowing balance is identified in the supplied text. Equity offerings generated approximately $57.0 million net in 2018.
Material changes and operating developments
- Revenue declined from 2017 as the company shifted toward internal product development and recognized remaining deferred revenue following termination of certain agreements in 2017.
- Operating cash use rose to $20.3 million, reflecting commercial infrastructure, R&D investment and grain purchases ahead of launch.
- Calyxt raised approximately $57.0 million net in a May 2018 follow-on offering. Cellectis, its majority shareholder, owned about 69.5% at year-end.
- The company contracted more than 17,000 acres with nearly 80 growers in Minnesota and South Dakota for high-oleic soybeans. It reported completing harvest and receiving a portion of the crop.
- High Fiber Wheat was in Phase II, with launch expected as early as 2022. Six candidates at Phase I or later had USDA confirmation of non-regulated status.
Outlook, risks and unusual items
Management estimated that year-end cash, cash equivalents and restricted cash would fund operations through at least early 2021, while cautioning that this estimate depends on assumptions and may be affected by cash burn, forward-purchase obligations and access to working capital. The company expected continuing significant losses and expenses; it did not provide quantified revenue or earnings guidance. Management said additional funding may be needed and may not be available on acceptable terms.
Key risks include execution and scaling of a third-party-dependent supply chain, farmer and food-company adoption, crop yields and weather, commodity-price exposure, evolving gene-editing regulation and public acceptance, competition, intellectual-property rights and reliance on Cellectis. Cellectis also has substantial governance and approval rights. Calyxt stated that a 10% change in commodity futures prices would change financial condition and results by about $0.9 million; it did not historically hedge this exposure.
Notable items: in May 2018, a settlement with Bayer terminated a license agreement and required Bayer to destroy covered technology and abandon specified patent applications. The headquarters sale-leaseback carries approximately $1.4 million annual base rent under a 20-year lease, with scheduled increases; Cellectis guarantees the lease subject to stated conditions. Grain forward-purchase commitments totaled approximately $12.4 million at year-end and were not recorded as a liability for undelivered grain. The company reported no other material pending legal proceeding. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an ICFR opinion.
Most important facts for investors to verify
- Confirm the issuer and filing: this is Calyxt, Inc. (NASDAQ: CLXT), not Cibus, Inc.
- Review 2019 product-sales performance, customer demand, realized pricing and whether the company achieved repeatable commercial-scale delivery.
- Assess the cash runway against actual operating cash use, restricted cash, lease payments and grain commitments; the early-2021 runway is management’s estimate.
- Track high-fiber wheat development, field-trial results, regulatory treatment and the timing and cost of planned launches.
- Evaluate Cellectis’ control, related-party arrangements, license royalties and the company’s dependence on licensed intellectual property.